The Bacteriology/Parasitology Core will provide vaginal cultures for facultative and anaerobic microorganisms in support of projects 1 (Patton, primate model) and 3 (Klebanoff, H2O2-peroxidase-halide), as well as cultures for Trichomonas vaginalis and Neisseria gonorrhoeae for the clinical core (Watts). This core, which will be directed by Dr. Sharon Hillier, the project P.I., will act as the centralized in vitro testing laboratory for microbicidal compounds. Microorganisms to be tested in vitro include sexually transmitted disease agents (N. gonorrhoeae and T. vaginalis), as well as constituents of the normal flora including Lactobacillus, Gardnerella vaginalis, Prevotella species, and group B Streptococcus. The effects of microbicidal compounds on pathogens including E. coil, Staphylococcus aureus and Candida albicans will also be evaluated. This core activity will provide information on the effects of microbicide concentration, length of exposure and pH on the in vitro killing observed. This information will be relevant to project 2 (McDougall, organotypic cultures model) for choosing the product concentration and length of microbicide exposure which is relevant for further testing. These studies will be compared to in vivo data generated in the monkey model (project 1). The Bacteriology/ Parasitology Core will provide in vitro testing of antimicrobial lipid mixtures generated by project 4 (Isaacs) to predict their range of specificity. This core is relevant to all four proposed projects and will provide novel insights into in vitro activity of microbicidal compounds tested after clinically relevant lengths of exposure, at pH ranges found in the vagina, at various concentrations, and in the presence or absence of blood.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Magee-Women's Hospital of Upmc
United States
Zip Code
Moncla, Bernard J; Guevara, Peter W; Wallace, James A et al. (2012) The inhibitory activity of typified propolis against Enterococcus species. Z Naturforsch C 67:249-56
Wang, Lin; Sassi, Alexandra Beumer; Patton, Dorothy et al. (2012) Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention. Drug Dev Ind Pharm 38:995-1007
Moncla, B J; Pryke, K; Rohan, L C et al. (2012) Testing of viscous anti-HIV microbicides using Lactobacillus. J Microbiol Methods 88:292-6
Moncla, Bernard J; Pryke, Kara; Rohan, Lisa Cencia et al. (2011) Degradation of naturally occurring and engineered antimicrobial peptides by proteases. Adv Biosci Biotechnol 2:404-408
Skinner, M C; Stamm, W E; Lampe, M L (2009) Chlamydia trachomatis laboratory strains versus recent clinical isolates: implications for routine microbicide testing. Antimicrob Agents Chemother 53:1482-9
Patton, Dorothy L; Sweeney, Yvonne T Cosgrove; Paul, Kathleen J (2009) A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 36:350-6
Sassi, Alexandra B; Isaacs, Charles E; Moncla, Bernard J et al. (2008) Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J Pharm Sci 97:3123-39
Moncla, B J; Pryke, K; Isaacs, Charles E (2008) Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (group B streptococcus), Haemophilus ducreyi, and vaginal Lactobacillus by 3-O-octyl-sn-glycerol. Antimicrob Agents Chemother 52:1577-9
Deslouches, Berthony; Gonzalez, Ivan A; DeAlmeida, Dilhari et al. (2007) De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 60:669-72
Patton, D L; Cosgrove Sweeney, Y T; McCarthy, T D et al. (2006) Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 50:1696-700

Showing the most recent 10 out of 42 publications